This metabolic rewiring is required for CDK12-dependent breast tumorigenesis and opens a therapeutic window for the treatment of otherwise therapy-refractory CDK12-overexpressing breast cancers, as demonstrated in retrospective cohort studies of real-life breast cancer patients and in prospective preclinical investigations in patient-derived xenograft (PDX) models. The gene discussed is CDK12; the disease is breast carcinoma.